Literature DB >> 18161747

Innate immunity in inflammatory bowel disease: a disease hypothesis.

D J B Marks1, A W Segal.   

Abstract

Crohn's disease arises from a defective interaction between the highly concentrated mass of bacteria in the gastrointestinal tract and the underlying tissues. It has generally been believed to result from an excessively exuberant inflammatory response or from 'autoimmunity'. Recent evidence has emerged that the problem is instead a failure of the way in which the body responds to the penetration of bacteria and other bowel contents through the intestinal mucosal barrier. Rather than Crohn's disease being caused by excessive inflammation, the primary mechanism is actually that of an immunodeficiency. Failure of inflammatory mediator production leads to insufficient recruitment of neutrophils, resulting in inadequate removal of bacteria and other debris. This impairment of acute inflammation can be compensated in some circumstances by signalling through NOD2. If not cleared, the foreign material in the bowel wall is taken up within macrophages, eliciting a granulomatous reaction and the local and systemic sequelae so characteristic of Crohn's disease. 2007 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18161747      PMCID: PMC2635948          DOI: 10.1002/path.2291

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  70 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Sargramostim for active Crohn's disease.

Authors:  Joshua R Korzenik; Brian K Dieckgraefe; John F Valentine; Diana F Hausman; Mark J Gilbert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

3.  Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease.

Authors:  Dermot P B McGovern; Pirro Hysi; Tariq Ahmad; David A van Heel; Miriam F Moffatt; Alisoun Carey; William O C Cookson; Derek P Jewell
Journal:  Hum Mol Genet       Date:  2005-03-24       Impact factor: 6.150

Review 4.  Interleukin-6: from basic science to medicine--40 years in immunology.

Authors:  Tadamitsu Kishimoto
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

5.  Defective acute inflammation in Crohn's disease: a clinical investigation.

Authors:  Daniel J B Marks; Marcus W N Harbord; Raymond MacAllister; Farooq Z Rahman; Jodi Young; Bissan Al-Lazikani; William Lees; Marco Novelli; Stuart Bloom; Anthony W Segal
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

Review 6.  Serologic markers in inflammatory bowel disease.

Authors:  Xavier Bossuyt
Journal:  Clin Chem       Date:  2005-12-08       Impact factor: 8.327

7.  Association of glycogen storage disease 1b and Crohn disease: results of a North American survey.

Authors:  Brian K Dieckgraefe; Joshua R Korzenik; Asif Husain; Lisa Dieruf
Journal:  Eur J Pediatr       Date:  2002-08-13       Impact factor: 3.183

8.  The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease.

Authors:  Stephan Brand; Tanja Staudinger; Fabian Schnitzler; Simone Pfennig; Katrin Hofbauer; Julia Dambacher; Julia Seiderer; Cornelia Tillack; Astrid Konrad; Alexander Crispin; Burkhard Göke; Peter Lohse; Thomas Ochsenkühn
Journal:  Inflamm Bowel Dis       Date:  2005-07       Impact factor: 5.325

9.  Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease.

Authors:  Keiko Yamazaki; Masakazu Takazoe; Torao Tanaka; Toshiki Kazumori; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

10.  The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease.

Authors:  Andrew P Cuthbert; Sheila A Fisher; Muddassar M Mirza; Kathy King; Jochen Hampe; Peter J P Croucher; Silvia Mascheretti; Jeremy Sanderson; Alastair Forbes; John Mansfield; Stefan Schreiber; Cathryn M Lewis; Christopher G Mathew
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

View more
  30 in total

1.  Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis.

Authors:  Ning Lu; Lihong Wang; Hailong Cao; Liping Liu; Luc Van Kaer; Mary K Washington; Michael J Rosen; Philip E Dubé; Keith T Wilson; Xiubao Ren; Xishan Hao; D Brent Polk; Fang Yan
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

2.  Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease.

Authors:  C B Larmonier; M T Midura-Kiela; R Ramalingam; D Laubitz; N Janikashvili; N Larmonier; F K Ghishan; P R Kiela
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

3.  The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells.

Authors:  Amy L Richmond; Amrita Kabi; Craig R Homer; Noemí Marina-García; Kourtney P Nickerson; Alexey I Nesvizhskii; Arun Sreekumar; Arul M Chinnaiyan; Gabriel Nuñez; Christine McDonald
Journal:  Gastroenterology       Date:  2012-02-28       Impact factor: 22.682

4.  The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Authors:  Mark S Moehle; João Paulo Lima Daher; Travis D Hull; Ravindra Boddu; Hisham A Abdelmotilib; James Mobley; George T Kannarkat; Malú G Tansey; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-29       Impact factor: 6.150

5.  Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis.

Authors:  Ariel Munitz; Eric T Cole; Amanda Beichler; Katherine Groschwitz; Richard Ahrens; Kris Steinbrecher; Tara Willson; Xiaonan Han; Lee Denson; Marc E Rothenberg; Simon P Hogan
Journal:  Gastroenterology       Date:  2010-04-14       Impact factor: 22.682

Review 6.  Leukocyte-epithelial interactions and mucosal homeostasis.

Authors:  Jason D Matthews; Caroline M Weight; Charles A Parkos
Journal:  Toxicol Pathol       Date:  2013-11-27       Impact factor: 1.902

7.  Salmonella Typhimurium type III secretion effectors stimulate innate immune responses in cultured epithelial cells.

Authors:  Vincent M Bruno; Sebastian Hannemann; María Lara-Tejero; Richard A Flavell; Steven H Kleinstein; Jorge E Galán
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

Review 8.  Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility.

Authors:  Josué Barahona-Garrido; Jorge Hernández-Calleros; Ignacio García-Juárez; Jesús K Yamamoto-Furusho
Journal:  Saudi J Gastroenterol       Date:  2009 Jul-Sep       Impact factor: 2.485

9.  Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease.

Authors:  Andrew M Smith; Farooq Z Rahman; Bu'Hussain Hayee; Simon J Graham; Daniel J B Marks; Gavin W Sewell; Christine D Palmer; Jonathan Wilde; Brian M J Foxwell; Israel S Gloger; Trevor Sweeting; Mark Marsh; Ann P Walker; Stuart L Bloom; Anthony W Segal
Journal:  J Exp Med       Date:  2009-08-03       Impact factor: 14.307

10.  New treatment options in the management of IBD - focus on colony stimulating factors.

Authors:  Josué Barahona-Garrido; Jesús K Yamamoto-Furusho
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.